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Abstract
Improving the proliferation of probiotics (ca.Bifidobacterium) and inhibiting the growth of
pathogenic bacteria (ca.Escherichia coli) is crucial for human health. This study demonstrates the
fabrication of core–shell structure fibers using electrohydrodynamic 3Dprinting to help improve
gastrointestinal tractmicrobial content. Thesefibers have various geometries and are capable of
encapsulating stachyose into cellulose acetate (shell layer) and loading proteoglycan into polyacrylic
resin II (core layer). The impact ofmembrane geometry on drug release behavior and the effect of
exchanging the loading site on physicochemical properties of the resultingfibers were studied. The
printedfibrousmembranes possess a biphasic drug release profile in simulated intestinal fluidwith a
burst release within the first 12 h and a slower sustained release up to 72 h. The speed order priority for
drug release rate of the printedmembranewaswhole-circle>semi-circle>square.Moreover, the
membranes exhibit good biocompatibility on L929 cells and excellent improvement effects on
Bifidobacterium bifidum, combining inhibition effects onEscherichia coli. In summary, the dual-drug
fibrousmembranes presented here and their precision-fabricated patterns pave a newdirection for
improving the gastrointestinal tractmicrobial ecosystemhealth in the human body.
1. Introduction
For humans, the gastrointestinal tract is a complex
microbial ecosystem and crucial for maintaining
human health [1]. The tract comprises a trillion
microbial cells across approximately 1000 species [2].
These cells colonize in the gut in a naturally commen-
sal way [3]. In the order of numerical majority, these
bacterial species are classified in the following bacterial
phyla: Firmicutes, Bacteroidetes, Actinobacteria, Proteo-
bacteria, Verrucomicrobia and Fusobacteria [4]. The
gastrointestinal microbiota can not only provide a
source of energy for biogenesis [5] and biosynthesize
vitamins [6], but it can also provide essential nutrients
and promote digestion of cellulose and angiogenesis
[1]. However, the gastrointestinal microbiota can be
potentially harmful to the host when the gastrointest-
inal microbial ecosystem undergoes abnormal
changes-symbiosis, resulting in obesity, allergies, dia-
betes, bowel inflammation, and even cancer [7, 8].
Thus, only in a harmonious symbiotic relationship
can the host’s well-being be offered from gastrointest-
inalmicrobiota.
Probiotic (meaning ‘for life’) [9], is defined as ‘live
microorganisms that, when administered in adequate
amounts, confer a health benefit on the host’ [10].
FAO/WHO confirmed probiotic possessed health-
promoting effects on its host by modulating the
microbiota [11]. Probiotics provide abundant positive
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the gut defense system and contributing to maintain-
ing normal gut function [1]. Bifidobacterium genus is
one of the most frequently used human probiotics
[12]. Previous studies have confirmed that there is a
positive correlation between low levels of Bifidobacter-
ium and many diseases. Patients with long-term
asthma [13], obesity children [14], or cystic fibrosis
[15] have been associated with low levels of Bifido-
bacterium. While, over dose of pathogenic Escherichia
coli (E. coli) will result in bloody diarrhea, dysentery,
and urinary tract infection [16], even meningitis et al
[17]. Thus by improving Bifidobacterium proliferation
and inhibiting E. coli propagation it is possible tomod-
ify the gastrointestinal microbial ecosystem and then
improve the hosts’health.
Stachyose (STA) belongs to tetrasaccharide, and
has proven its advantage in the proliferation of Bifido-
bacerium as well as in maintaining gut microbiota and
anti-cancer therapeutics [18]. Proteoglycan (PRO) is a
kind of glycosylated glycoprotein consisting of a core
protein that is linked to glycosaminoglycan chain(s)
through covalent bonding [19]. The inhibition effect
of PRO fromGanoderma lucidum spore powder (GLSP)
on E. coli has been confirmed in the works of Zhu et al
[20]. Thus, using PRO from GLSP to inhibit the pro-
liferation of E. coli is a reasonable choice to exert the
prominent antibacterial effects and minor side effects
of the natural products.
Electrohydrodynamic (EHD) 3D printing pos-
sesses the benefits that creates well-ordered and custo-
mized/personalized geometries through digitally
controlled deposition ofmaterials [21, 22]. The advan-
tages of EHD printing over other 3D printing technol-
ogies have been demonstrated. EHD 3D printing
enables micro to nano scale fiber engineering and
alignment using a range of materials; achieved at the
ambient temperature [23]. Moreover, this process also
enables control and development of complex struc-
tures, such as core–shell and Janus fibers, using con-
centrated organic/polymer solutions [24]. Moreover,
printed 3D fibrous films comprise precisely stacked
and aligned fibers with varied inter-connected void
space or geometry which can impact drug release
[25, 26]. Several new types of personalized capsules
comprising printed layers, with each layer having a
distinctive function or drug component, can be used
for targeting and detection applications once given
through the oral route [27]. Printed fibrous films can
be loaded into an enteric- or gastric-dissolvable cap-
sule. In this work, fibers were encapsulated into an
enteric capsule and then tested as a common oral
delivery system [28].
Herein, cellulose acetate (CA) and polyacrylic
resin II (PRII) were used as excipient materials of
enteric-specific medicine due to its good biocompat-
ibility [29], nontoxicity [28], and pH dependent [30]
characteristics. The CA encapsulating stachyose (CA-
STA) was used as shell while PRII loading proteogly-
can (PRII-PRO) was used to form the core of the
fibrous structures. The release of PRO is able to inhibit
the growth of E. coli, and the release of STA will
improve the proliferation of Bifidobacterium. Specifi-
cally, the core–shell membrane with three kind of geo-
metries (square grid, semi-circle, and whole-circle)
was fabricated and effect of exchange at the loading
site between stachyose and proteoglycan on physico-
chemical properties was investigated. The membrane
with these various geometries can be released in a con-
trollable manner and show significant proliferation




CA (Mw=31 104 g mol−1) was obtained from
Sigma-Aldrich (St Louis, USA). PRII (powder, viscos-
ity=13 mPa s, pH=5.0) and STA (85%) were
purchased from Shanghai Yuanye Bio-Technology
Co., Ltd (Shanghai, China). PRO was prepared from
uncracked GLSP and its main components (including
amino acids, monosaccharide) have been detailed in
previous findings [20]. Ethanol (100%), acetone,
N,N-dimethylformamide (DMF), HCl solution, phos-
phate-buffered saline (PBS, pH=7.4) were all pur-
chased from Sinopharm Chemical Reagent Co., Ltd
(Shanghai, China). Modified eagle medium (MEM)
was supplied by Gibco (Gibco, Carlsbad, California,
USA); and fetal bovine serum (FBS) was purchased
from Sijiqin (Sijiqin, Hangzhou, China). Deionized
water (DI water) was obtained in-house from ultra-
pure water purifier (MilliporeMilli-Q, Bedford, USA).
Cell Counting Kit-8 (CCK-8) was purchased from
Dojindo Molecular Technologies, Inc. (Kumamoto,
Japan). E. coli (NW1014 (8099)) was purchased from
Nanjing Maojie Microbiology Technology Co., Ltd
(Jiangsu, China). Nutrient Broth and Violet Red Bile
agar were purchased from Qingdao Hope Bio-Tech-
nology Co., Ltd (Shandong, China). Bifidobacterium
bifidum (ATCC 29521) and TPY Fluid Medium were
supplied by Shanghai Acmec Biochenical Co., Ltd
(Shanghai, China). Rhodamine B (95%) and BBL
agar medium base was purchased from Solarbio Life
Science (Beijing, China). All chemicals and reagents of
analytical grade.
2.2. Preparation of printing solutions
CA solution was prepared by dissolving CA powder in
a mixture of acetone/DMA (acetone/DMF=1:1,
v/v) at a concentration of 20% (w/w) by magnetic
stirring (VELP ARE heating magnetic stirrer, Italy) for
12 h at 200 rpm. PRII solution was prepared by
dissolving PRII powder in ethanol at a concentration
of 20% (w/w) by magnetic stirring for 12 h (at
200 rpm). STA (5 w/w % of CA) was dissolved into
100 μl DI water and then added to the CA solution and
mixture under gentle stirring at 100 rpm for 4 h to
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obtain a homogenous CA-STA solution for EHD
printing. PRO (5 w/w % of PRII) was dissolved into
150 μl DI water and then added to the PRII solution
and mixture under gentle stirring (at 100 rpm) for 4 h
to obtain a homogenous PRII-PRO solution for EHD
printing.
2.3. Preparation of PRII-PRO/CA-STA composite
membrane
Figure 1(a) shows the coaxial EHD 3D printing
apparatus used to prepare the PRII-PRO/CA-STA
composite membrane. The EHD 3D printing set-up
consisted of a programmable X–Y–Zmovement stage,
a high power voltage supply (Glassman High Voltage
Inc. series FC,USA), two syringe pumps (KDScientific
KDS100, USA), and a coaxial stainless steel nozzle,
which consists of inner and outer needles having
internal/external diameters of 0.2/0.4 and 0.9/
1.2 mm, respectively. The collector was placed on the
X–Y–Zmovement stage controlled by a mechatronics
controller. For EHD3Dprinting, theCA-STA solution
and PRII-PRO solutionwere loaded into the outer and
inner needle at the speed of 0.45 ml h−1 and
0.15 ml h−1, respectively to form core/shell fiber
(figure 1(c)). The distance between the collector and
nozzle tip was ∼5 mm, and the voltage applied to the
nozzle was 2.5 kV. The printing speed (the movement
of collector stage followed a pre-determined pattern)
of the pre-determined shape was 20 mm s−1. Three
kinds of patterned fibrous membranes (square grid,
semi-circle, and whole-circle) with 10-layer deposi-
tion (average thickness: 61.5±2.6 μm) were gener-
ated. The top view and front view are shown in
figures 1(d) and (e), respectively. The inter-connected
void space between two fibers was 500 μm and the
radius ofminimumcircle was 3 mm (figure 1(f)).
2.4. Fibermorphology assessment
The surface morphology of printed membranes was
assessed using optical microscope (OM, phoenix
BMC503-ICCF, China) and SEM (Quanta FEG650,
FEI, Netherland). Before SEM observation, samples
were sputter-coated with a gold layer using 108 Auto
Cressington Sputter Coater, Ted Pella, Inc. The
samples were coated for 60 s with current of 25 mA,
and the resulted SEM images were obtained using an
accelerating voltage of 20 kV. The fiber diameter
distribution was calculated using ImageJ software
(National institute of Health, MD, USA) from ran-
domly selected 50 fibers of each structure, and the
statistical results was plotted using Original software
(Original lab, USA).
2.5. Fourier transform infrared (FT-IR)
spectroscopy
The FT-IR spectra of CA, PRII, STA, PRO, and their
formulations (CA/PRII, PRII-PRO/CA-STA) were
obtained using FT-IR spectroscopy (IR Affinity 1,
Figure 1. Schematic diagramof core–shell EHD3Dprinting system (a); forming process of continuous core–shell stable-jetmode at
different applied voltages (b): i at 0 kV, ii at 1 kV, iii (front view) at 2.5 kV and iv (side view) at 2.5 kVwhenfiberwas printed at
20 mm s−1, respectively; core–shellfiber with two types of drug-loadingmodels (c): i—PRII-PRO/CA-STA, ii—PRII-ST/CA-PRO
A; top view of patternedfibrousmembrane with various geometries (d): i—square, ii—semi-circle, iii—whole-circle; the front view of
patternedmembrane (e) corresponding to i, ii, and iii of (d); characteristics ofmembrane (f): i, the space between two printed fibers; ii,
the radius of curves, and iii was the printed fiberwith straight line and/or curve.
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Shimadzu, Japan). The spectrum of each sample was
recorded within the scanning range 4000–400 cm−1 at
a resolution of 4 cm−1 with an average of 20 scans.
2.6. X-ray diffraction (XRD)
The physical form of each component (CA, PRII, STA,
PRO) and their formulations (CA/PRII, PRII-PRO/
CA-STA) were determined using x-ray diffractometer
(Gemini A OHra, Oxford Varian, UK). The XRD
spectra of samples were obtained via scanning at 2
theta of 3°–65° with deploying step of 0.02° under the
analyzing voltage of 40 kV and current of 30 mA.
2.7. Thermogravimetric analysis (TGA)
The thermal stability of each component (CA, PRII,
STA, PRO) and each formulation (CA/PRII, PRII-
PRO/CA-STA) were investigated using TGA/DSC1
device (Mettler-Toledo, UK). Test results were
obtained with the temperature in the range from 30 to
600 °C at heating step rate of 10 °C min−1 under the
flowof nitrogen gas.
2.8. Tensile test
The mechanical properties of samples were deter-
mined by a universal materials tester (Zwick/Roell
Z020, Zwick, Germany). Samples (ca. 20 mm×
20 mm) with various geometries (square, semi-circle,
and whole-circle) were performed with a load cell of
500 N and crosshead speed of 10 mmmin−1 at 25 °C.
The thickness of each sample was measured using a
measuring gauge (PD-CT1, Powered Technology Co.,
Ltd, Beijing, China).
2.9. Contact angle analysis
The hydrophilic properties of the printed membranes
was determined using an optical contact angle meter
(SJ200KB, KINO Industry Co., Ltd, USA). The water
contact angle of resulting membrane was measured
using sessile-drop mode with PBS solution at 25 °C
and calculate the average value of left and right water
contact angle at each time point to represent the angle
of each sample. Each experiment was performed in
quadruplicate.
2.10.Drug release study in vitro
The drug release behavior of three kinds of geometries
(square, semi-circle, whole-circle) fibrous membrane
was examined in vitro, which was loaded drug content
(5%w/w) theoretically.
The loading capacity (LC) and encapsulation effi-
ciency (EE) of STA or PRO were measured via
equations (1) and (2) according to the previous
work [31].
where total amount of STA content encapsulated in
fibre was measured using UV spectrophotometer
(UV-2600 spectrophotometer, Shimadzu, Japan) at a
wavelength of 190 nm [32]. The content of PRO was
measured at 595 nm using Bradford method [33]
through a Bio-Rad protein assay reagent (Bio-
Rad, USA).
For the drug release study, PBS (pH=7.4) was
used to prepare simulated intestinal fluid (the release
medium) [28]. Briefly, sample (the printed fibrous
membrane) was immersed in 10 ml of the release
medium and was gently agitated (at 100 rpm) using a
thermostatic oscillator (DDHZ-300, Suzhou Peiying
experimental equipment Co., Ltd, Suzhou, China) at
37±0.5 °C. At pre-determined intervals, 3 ml of the
drug release mediumwas removed for UV absorbance
analysis and this sample was replenished with 3 ml of
fresh medium. The concentration of the drug released
was calculated according to fitting equation (figure S1
is available online at stacks.iop.org/BF/12/025026/
mmedia). Each experiment was performed in tripli-
cate. The cumulative release percentage of STA or
PROwasmeasured by equation (3) [34]:
( ) ( )/= ´m mMass release % 100%, 3t s
where, mt was the weight of released agent (STA or
PRO) at time point t,ms was the weight of agent (STA
or PRO) loaded in themembrane.
2.11. Effects on cell viability evaluation
L929 cells (mouse fibroblasts cell line, obtained from
American Type Culture Collection, ATCC) were used
to evaluate the biocompatibility of resulting mem-
brane, which provide initial biocompatibility informa-
tion on sample concentrations [35]. L929 cells were
cultured in MEM solution supplemented with 10%
FBS and 1% antibiotic-antimycotic in a culture dish
(Φ=10 cm) at 37±0.5 °C, in 5% CO2. The culture
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The effects of resulting membrane on viability of
L929 cells were measured using a CCK-8 kit. Briefly,
cells (1.0×105 cells ml−1) were seeded into 96-well
plates for 24 h and were then co-cultured with various
concentration ofmembranes. Since all samples consist
of the same formulation, typical samples (square
membrane) were pulverized using a mortar and pestle
andwere then disinfected using UV irradiation for 4 h.
After being co-cultured for 48 h, the optical density
(OD)wasmeasured using amicroplate reader (Spectra
Max 190, NanoDrop, USA) at 450 nm and the cell via-
bility was calculated according to the equation showed
inCCK-8 kitmanufacture instructions.
To visualize the effects of the printed drug-loaded
membrane on cell morphology, fluorescence micro-
scopy (Nikon, Ti-S, Tokyo, Japan)was used to obtain
fluorescence image of L929 cells after being incu-
bated with the membranes. Briefly, L929 cells were
stained with alexar fluor 546 phalloidin (Invitrogen,
Carlsbad, California US) and 4′,6′-diamidino-2-phe-
nylindole hydrochloride (DAPI, Invitrogen) staining
reagents after being co-cultured with the membrane
for 48 h.
2.12. Assessment improvement effects on
bifidobacterium and inhibition effects on E. coli
in vitro
The ability of the resulting printed membranes on
improving proliferation of Bifidobacterium was
assessed by aerobically inoculating Bifidobacterium
bifidum into TPY medium at 36.5±0.5 °C for 24 h
using a biochemical incubator (SHP080, Shanghai
Jinghong experimental equipment Co., Ltd). The
pulverized and disinfected drug-loaded samples (0.5 g
and 1 g of printedmembrane) and TPY FluidMedium
(10 ml) were introduced to a test tube. 5 μl of the
inoculated TPY suspension was added to the test tube
and this was cultured in the biochemical incubator
again at 36.5±0.5 °C for 24 h. The control group and
negative group (fibers without drug) were performed
and compared. Following 24 h culturing, theOD value
of B. bifidum was determined using a microplate
reader at 650 nm using a modified method that was
developed by Lu et al [34, 36]. The pH value of each
tube was measured using a pH-meter (inoLab pH,
WTW, Germany) and the viable count on the surface
of BBL agar medium base was observed using the plate
coatingmethod following culture period of 48 h.
The E. coli strain was aerobically pre-cultured in a
nutrient broth for 24 h in an incubator. The pulverized
and disinfected drug-loading membrane (1 g, 0.5 g)
and nutrient broth (10 ml)were added into a test tube.
Again, the OD value of E. coli was determined at
650 nm. The strain suspension was used to coat the
surface of Violet Red Bile agar and the printed mem-
brane was placed on the coated surface. The inhibition
zone was observed following 48 h of culture in the
incubator.
2.13. Statistical analysis
All experiments were performed in triplicate for each
sample and data is given asmean± standard deviation
(n=3). Statistical analysis was performed using SPSS
software (SPSS Statistics v18, IBM, UK) by Student’s t-
test. Differences in significance are labeled as
*p<0.05, **p<0.01, and N.S. (not significant,
p>0.05). All the statistical plots were plotted using
Origin software (OrginLab, USA).
3. Results and discussion
3.1.Morphology assessment of drug-loading
membrane
Although PRII has been used in tablets [30], the
encapsulation of polyacrylic resin into core–shell
fibers is still challenge. Therefore, the feasibility of
fabricating PRII fibers using EHD 3D printing has
been investigated here. As results shown in figure 1(b),
a typical Taylor cone was achieved at the optimum
electrical potential (∼2.5 kV) at a collection distance of
∼5 mm. The printed fibers with core–shell structure
can be observed via optical microscopy by replacing
PRO with Rhodamine B into loaded PRII-core layer,
as shown in figure 2(a), confirming core/shell struc-
ture existing. The diameters of core and shell layers
were measured using printed structures shown in
figure 2(a). The diameters of inner and outer shell were
10.8±3.7 μm and 61.2±6.2 μm, respectively. The
coarser outer shell diameter is due to the difference
between outer needle (0.9 mm) compared to the inner
needle diameter (0.2 mm). Moreover, the flow rate of
outer needle was 0.45 ml h−1, which was higher than
that of the inner solution (0.15 ml h−1).
Alongside this, the impact of geometry of the prin-
ted fibrous membrane on the diameter distribution of
fiber was also studied. Here, the diameter distribution
of the printed fibers with various geometries (square,
semi-circle, and whole-circle) were calculated and
presented in figures 2(b1)–(b3), respectively. The
mean diameters of square, semi-circle, and whole-
circle were 72.5±16.2 μm, 68.9±16.8 μm,
56.2±10.0 μm, respectively. This indicates that an
increase in the circle proportion (structure) can
reduce fiber diameter. When printing a whole-circle
structure, the path length between two points linked
with curve was longer than that of a straight line
(square structure). Thus, when the flow rate is kept
constant, diameter of curve line is reduced as can be
observed. The printing time is longer for a curve line
compared to that or a straight line, when the moving
speed is constant. This improved the solvent volatili-
zation in each fiber before multi-layer deposition.
Parameters such as working distance, solution con-
centration and collector movement speed are crucial
with fiber morphology as these can affect the drying
time of the fibers [37]. Moreover, the mean diameter
of non-loaded fibers (figure S2) was smaller than that
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of corresponding drug-loaded fibers. This is due to
the concentration and viscosity of pristine polymer
solution being lower which also exhibits a reduced
liquid surface tension [38], resulting in thinner fiber
diameter.
Figure 3 shows themorphology of the drug-loaded
composite membranes. As the optical images
(figures 3(a1)–(c1)) shown, ultrafine and aligned fibers
were obtained. The SEM images (figures 3(a2)–(c2))
reveal the engineered structures were printed pre-
cisely, and the inset images indicate the fibers aligned
precisely and possessed smooth surface.
3.2. FT-IR, XRD, Tensile test, andTGA results
Possible interactions between functional groups in the
polymer matrix and loaded drug during the printing
process were evaluated using FT-IR technique. FT-IR
is an effective and non-destructive method to examine
such potential interactions [39]. Figure 4(a) shows the
FT-IR spectra of all samples to examine the composi-
tion and material stability of membrane. For pure CA,
the characteristic absorbance peak at 1755 cm−1,
corresponded to the stretching of the C=O bond [40].
The peaks observed at 1373 cm−1 and 1045 cm−1 were
symmetric vibration of C–CH3 and single bond
vibration of C–O, respectively [41, 42]. For pure PRII,
the peak of C–O stretching showed at 1350 cm−1,
while the characteristic peak showed at 1720 cm−1 was
the overlap of C=O present in the acrylic group and
polyamic acid [43]. The FT-IR spectra of PRO, the
absorbance peaks showed at 1527 and 1664 cm−1
indicate the presence of amide II and amide I
respectively, revealing the presence of a fraction of
protein [44]. The sharp absorption peaks located at 2920
and 1620 cm−1 were the vibration of C–Hand –COOH,
respectively [45]. The FT-IR spectra for pure STA was
muchmore complicated. The strong peaks showed near
3400 cm−1, indicate the inter- and intramolecular inter-
action between the –OH, –H and polysaccharide chains
[46]. For the FT-IR spectra of core/shell composite
membrane PRII-PRO/CA-STA, themain characteristic
peaks of each component were detected, indicating the
membrane loaded with multiple drugs was fabricated
successfully and there was no interaction between the
components indicating chemical stability during the
printing process. This is consistent with the results of
Wu et al [28].
XRD (shown in figure 4(b)) is capable of indicating
the crystalline nature changes induced by the EHD 3D
printing process. For pure CA, four sharp diffraction
peaks found at 8.3°, 10.4°, 13.3° respectively indicate
the CA powder was semi-crystalline [47]. For pure
PRII, STA, and PRO, broad diffraction peaks appeared
at around 14.1°, 17.3°, 20.5°, respectively, which indi-
cate these materials (PRII, STA, and PRO) exhibit less
crystallinity than CA [39]. The diffraction peak of the
printed membrane was is absent, indicating STA and
Figure 2.The optical images of printed fibrousmembranewith square geometry (a); diameter distribution offibers with various
geometries (b1) square, (b2) semi-circle, and (b3)whole-circle.
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PRO were in an amorphous state in the printed mem-
brane, suggesting this amorphous nature is conducive
to drug release [25].
Prior to tensile testing, the thickness of each sam-
ple wasmeasured. The thicknesses of square, semi-cir-
cle, andwhole-circlemembranes were 64.4±2.6μm,
61.9±4.2 μm, and 58.1±2.5 μm, respectively.
Figure 4(c) shows tensile curves for all samples where
ductile failure can be observed [48]. However, zig-zag
patterns in tensile curves are more prominent for
membrane sandwich structure shown in figure 4(c).
This suggest that the shape and void arrangement of
fibers are important factors in the overall mechanical
properties of printed structures [28]. The maximum
tensile strengths of whole-circle, square membrane,
and semi-circle membrane were 3.3 MPa, 2.9 MPa,
and 2.3 MPa, respectively. The broken strains of
whole-circle, square membrane, and semi-circle
membrane were 27.3%, 6.1%, and 12.7%,
respectively. It is noted that maximum tensile
strengths and broken strains increased as the circle
proportion increased. This is most likely due to the
fact that the fibers with circular pattern would
morph into a straight line under tensile force. In addi-
tion to this, the maximum tensile strength of the three
kinds of composite membrane was greater than
0.22 MPa [49], which is the gastrointestinal pressure of
in humans, indicating the printed membranes can
preserve their shape for potential gastrointestinal
application.
The results of thermal stability analysis is shown in
figure 4(d). For CA, PRII, and composite membrane
(PRII-PRO/CA-STA), the weight loss process occur-
red in three stages. For CA, about 6.7% was lost
between 30 °C and 310 °C because of evaporation of
trapped moisture and other volatiles in the material.
The weight lost (∼71.5%) between 310 °C and 382 °C
can be attributed to unzipping of carbon bonds to
Figure 3.Optical images (a1)–(c1) and scanning electron images (a2)–(c2) of printing fibers loading STA and PROwith various
patterns: (a1) and (a2), square; (b1) and (b2), semi-circle; (c1) and (c2), whole-circle.
7
Biofabrication 12 (2020) 025026 L-FZhu et al
form low molecular weight volatile organics [43]. For
PRII, the initial weight loss event occurred between
30 °C and 380 °C, resulting in 15.8% weight loss with
80.1% being lost between 380 °C and 464.3 °C. The
weight loss events of the composite membrane was
very similar to that of CA with approximately 10.2%
and 56.7% weight being lost during the first and sec-
ond stage, respectively.
The TGA thermograms of STA and PROwere very
similar. The initial weight loss event was mainly
Figure 4. FT-IR spectra (a), XRD spectra (b), tensile strain (c) andTGA results (d) of printed fibers and rawmaterials.
Figure 5. (a)Water contact angle images of fibrousmembrane loading drug in themanner of PRII-PRO/CA-STA at various time
point: 0 s, 30 s and 60 s, (first column infigure 5(a): top view of patternedmembranewith various geometries; red dot presents the
position of water drop forwater contact angle test); (b)figure (a) expressedwith column chart.
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ascribed to water absorption on the surface and water
bound to polymeric chains [50] whilst the second
weight loss event was due to the degradation of the sac-
charide units [51].
3.3. Contact angle analysis
Contact angle analysis is vital as the degree of hydro-
philicity can influence drug release and bio-related
applications [52]. The mean value of water contact
angle was measured at 4 points of the samples to
determine hydrophilicity of the compositemembrane.
As the results show in figure 5(a), the initial water
contact angles for square membrane, semi-circle
membrane, and whole-circle membrane were 80.4°,
59.1°, and 52.8°, respectively, indicating all samples
possessed adequate hydrophilic characteristics with
good wettability as the angles were smaller than 90°
[52]. The contact angle values steadily decreased over
time from 0 s to 60 s. Moreover, initial contact angles
(at 0 s) of membrane composite fibers without drugs
were greater than that of the drug-loaded membrane,
Figure 6.Digital images of printed fibrousmembranewith various geometries: (a) square, (b) semi-circle and, (c)whole-circle. The
printed fibrousmembranes were encapsulated into capsule ((a′), (b′), (c′)was corresponding to (a), (b), (c), respectively). Drug release
profiles for (a1) STA and (a2)PRO fromPRII-PRO/CA-STA (STA and PROwere loaded in outer layer and inner layer, respectively);
drug release profiles for (b1) STA and (b2)PRO fromPRII-STA/CA-PRO (PROand STAwere loaded in outer layer and inner layer,
respectively).
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reaching 104.0°, 102°, and 93.7° for square, semi-
circle, and whole-circle, respectively (see figure S3).
This confirms that the hydrophilicity of membrane
was improved by encapsulating STA and PRO, as they
are naturally hydrophilic.
3.4.Drug release
Figures 6(a)–(c) show the printed structures of square
membrane, semi-circle membrane, and whole-circle
membrane before being encapsulated into capsules
(figures 6(a′)–(c′)). The fibers were encapsulated into
an enteric capsule and then tested as a common oral
delivery system. The in vitro drug release was carried
using PBS solution (pH=7.4) to mimic intestinal
fluid [28]. The LC for STA and PRO was 3.67±0.1%
and 1.1±0.02%, respectively; and the EE was
90.3±1.7% and 95.3±0.5%, respectively. This
confirms each drug was efficiently loaded into outer
layer and inner layer, respectively.
As shown in figures 6(a1) and (a2) (PRII-PRO/
CA-STA, STA and PRO were loaded in outer and
inner layers, respectively), all samples presented a
biphasic release profile which consisted of an initial
burst release phase (within 12 h) and a slow release
period (12–72 h).Within the rapid release phase (12 h)
of STA (figures 6(a1) and (a2)), 78.7±1.9%,
81.5±3.4% and 83.6±2.3% was released from
square membrane, semi-circle membrane and whole-
circle membrane, respectively. After 72 h, the cumula-
tive release of all membranes was nearly 95±1.2%.
With respect to PRO after 12 h (figures 6(a1) and (a2)),
65.4±1.6%, 70.9±2.9% and 76.7±2.8% was
released from square membrane, semi-circle mem-
brane and whole-circle membrane, respectively dur-
ing the rapid release stage. Due to STA being
incorporated in CA (insoluble in PBS) and PRO being
encapsulated in PRII (soluble in PBS), the dissolution
of PRII is conducive to the drug release. This
demonstrates that the varied geometry of membrane
matrix affects the drug release behavior, confirming
the modulation of drug release through geometry of
matrix.
To explore the effects of the drug location in core–
shell fibers on release performance, we exchanged the
drug loading site: encapsulating STA into PRII-core
layer and loading PRO into CA-shell layer. As the
results show in figures 6(b1) and (b2), the release pro-
files were biphasic and similar to the results showed in
figures 6(a1) and (a2). Comparing the cumulative
release results of the drug before and after exchange
loading site, it is clear to see that the release of STA in
the core layer was faster than it did in the shell layer.
However, the opposite was observed with PRO
(figures 6(b1) and (b2)). The release from the shell
layer was quicker than the release from the shell. This
probably due to the excellent water solubility of STA
[53] combined with dissolution of PRII. The PRO loa-
ded in the outer shell layermakes it dissolve faster than
in the core layer due to increased contact area of outer
layer to release medium. Another thing to note is the
release of STA and PRO from the same patterned
fibrousmembrane is shown infigure S5.
To explore the STA/PRO release mechanisms, the
release profiles were fitted to the Korsmeyer-Peppas
model (figures S6 and S7) [54]. As shown in table 1, the
correlation coefficient (R2) indicates the release of STA
and PRO from fibrous membrane with loading drug
manner of PRII-PRO/CA-STA was primarily domi-
nated by Non-Fickian transport (n>0.45) except for
STA release from whole-circle geometry, which was
dominated by Fickian diffusion (n<0.45). Swapping
the drug loading site still found drug release to be
dominated by Non-Fickian diffusion (n>0.45)
mainly (table 2). This is due to water solubility of PRII
being greater than that of CA, and this influences STA
release from the core layer [54].
Table 1. Fitting parameters of STA and PRO fromfibrousmembranewith loading drugmanner of PRII-PRO/CA-STA.
STA PRO
Square Semi-circle Whole-circle Square Semi-circle Whole-circle
n 0.5612 0.4645 0.4286 0.6393 0.6043 0.5743
R2 0.9456 0.9273 0.9604 0.9714 0.9692 0.9684
k 27.41 32.42 38.36 18.56 21.99 26.30
Drug transportmechanism Non-F.T. Non-F.T. Fickian diffusion Non-F.T. Non-F.T. Non-F.T.
Table 2. Fitting parameters of STA and PRO fromfibrousmembranewith loading drugmanner of PRII-STA/CA-PRO.
STA PRO
Square Semi-circle Whole-circle Square Semi-circle Whole-circle
n 0.6843 0.5507 0.4597 0.5904 0.5553 0.5042
R2 0.9618 0.9468 0.906 0.9498 0.9538 0.9673
k 29.37 41.67 48.63 23.98 27.83 31.78
Drug transportmechanism Non-F.T. Non-F.T. Non-F.T. Non-F.T. Non-F.T. Non-F.T.
F.T. : Fickian transport.
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The SEM images of fibers with square pattern fol-
lowing in vitro release (figure S4(a)) showed uneven
morphology, which may be due to the solution of loa-
ded drug. The SEM images of cross-section images
(figure S4(b)) show hollow structures (labeled with red
circle), which was due to the dissolution of the inner
layer (PRII-PRO). This further verifies the core–shell
structure of the printed fibers. The proportion of core
layer was much smaller than the shell layer, which is
due to the internal needle diameter was 0.2 mm and
inner solution speedwas 0.15 ml h−1.
3.5. Biocompatibility evaluation
The effect of compositemembrane on the cell viability of
L929 cells was used to evaluate the biocompatibility of
printedmembranes using typical squaremembranes. As
the results show (figure 7(a)), the treatment groups with
various concentration (0.1, 1, 10mgml−1) exhibited
promising effects on cell viability. For the concentration
of 1mgml−1, 137.8% and 146.5% cell viability was
obtained from the treatment of PRII-PRO/CA-STA and
PRII-STA/CA-PRO, respectively. This is attributed to
proteins found in PRO, which exhibit good mitogenic
activity [55] andprotective effect onDNA [56]. Addition-
ally, the cell viability with the treatment of 10mgml−1
was lower than that of 1mgml−1. Thismay be attributed
to that the higher concertation (10mgml−1) increased
the osmotic pressure of the environment around the
cells, which could partially inhibit cell proliferation
due to the Warburg effect and inhibit mitochondrial
activity [57].
The effects of the drug-loaded membranes on
L929 cells morphology can be visualized through
fluorescence images (figure 7(b)). It can be seen that
the L929 cells in all samples exhibited uncompromised
cellular structures and extended morphology in all
various printed patterns. The L929 cells were able to
proliferate vividly both around the membrane and on
the surface of membrane. The cells also proliferated
very well when co-cultured with the drug-loaded
membranes with the drug loading sites exchanged
(PRO loaded in outer layer and STA loaded in inner
Figure 7. (a)Effects of printingmembrane on the cell viability of L929, (b)fluorescentmicrographs of L929 cells co-culturedwith
membranes loading drugmanner of PRII-PRO/CA-STAwith various patterns.
11
Biofabrication 12 (2020) 025026 L-FZhu et al
layer (figure S8)). This shows that both composite
membranes (PRII-PRO/CA-STA, PRII-STA/CA-
PRO) possessed good biocompatibility.
3.6. Improvement effects onBifidobacterium
bifidum
The OD value at 650 nm of TPY Fluid Medium
inoculated B. bifidum was total number of bacteria.
As shown in figure 8(a), the OD values of treatment
of PRII-STA/CA-PRO at 0.1 g and 0.05 g was
294.2±13.1% and 288.8±7.8%, respectively. The
treatment of PRII-PRO/CA-STA of 0.1 g and 0.05 g,
the OD value was 242.7±9.8% and 228.8±7.7%,
respectively. These results indicate that the improve-
ment effect of drug-loaded membrane on B. Bifidum
was significant. This may be attributed to the excellent
growth-promoting effect of stachyose, which can
enhance the Bifidobacterium proliferation speed
(approximately×40) by increasing the activity of α-
galactosidase [58, 59].
The effects of stachyose on the pH values corre-
sponded with the total number of bacteria in TPY
Fluid Medium. Among them, the corresponding
pH value decreased in a time-dependent and con-
centration-dependent manner. With the treatment of
PRII-STA/CA-PRO of 0.1 g, the pH values were
3.88±0.07 and 3.84±0.06 at 24 h and 48 h
(figures 8(b) and (c)), respectively. The pH value was
recorded at 4.01±0.05 and 3.97±0.03 after 24 h
and 48 h, respectively, when the concentration of
PRII-STA/CA-PRO decreased to 0.05 g. The decrease
in pH could be as a result of fermentation products
(e.g. lactic acid) of carbohydrate by B. bifidum, con-
firming the growth of B. bifidum. This is consistent
with the results of Shu et al [59], although the differ-
ences between treatment groups and control were not
significant, which may be mainly attributed to lactic
acid is monobasic weak acid [60]. The pH value was
lower with the treatment of PRII-STA/CA-PRO than
that of PRII-PRO/CA-STA, which may be due to that
the release rate of stachyose was much rapider when it
was loaded into the core layer (as drug release results
shown). This implied that the proliferation effects on
B. bifidum of PRII-STA/CA-PRO was better than that
of PRII-PRO/CA-STA.
Asfigure 8(e) shown, the viable colony counts on the
agar surface of the treatment groups are much denser
than that of control and negative groups (figure 8(d)),
confirming the proliferation ofB. bifidumwas enhanced
by stachyose. There was a significant difference between
Figure 8. (a)Effects of composite squaremembrane onODvalue ofBifidobacterium bifidum, pHof TPYFluidMedium after being co-
cultured for 24 h (b) and 48 h (c); plateBifidobacterium bifidum treated by (d) unloadedmembrane and (e)drug-loadedmembrane on
BBL agarmediumbase using plate coatingmethodwith cultured for 48 h.
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the treatment of PRII-STA/CA-PROandof PRII-PRO/
CA-STA, which may be due to issues with analyzing
viable counts indifferent size petri dishes.
Since the proliferation effects on B. bifidum of
PRII-STA/CA-PRO was better than that of PRII-
PRO/CA-STA, the proliferation effects of drug-load-
ing (PRII-STA/CA-PRO) semi-circle and whole-cir-
cle membrane on B. bifidum were explored. The OD
values (figure S9(a)) were recorded at 285.2±12.1%
and 277.8±9.8%, respectively at 0.1 g treatment
of semi-circle and whole-circle membrane. The
pH values were 3.83±0.06 and 3.8±0.06 at 48 h
(figure S9(d)), respectively at the treatment of 0.1 g
semi-circle and whole-circle membrane, respectively.
Besides, the proliferation effects on B. bifidum was
visible colony counts on the agar surface of the treat-
ment of semi-circle and whole-circle drug-loading
membrane (figures S10(c) and (d)).
3.7. Inhibition effects onE. coli
The total number of E. coli on Nutrient Broth was
compared with control and the results showed the
inhibition effects of printed square membrane on the
bacteria. As shown in figure 9(a), the OD value of
treatment of PRII-STA/CA-PRO with 0.1 g and 0.05 g
were 63.0±3.4% and 90.8±4.4%, respectively, with
respect to the control. For the treatment of CA- STA/
PRII- PRO with 1 g and 0.05 g, the OD values
were 63.5±7.9% and 85.5±6.1%, respectively. This
indicates the improvement effect of drug-loading mem-
brane on E. coliwas significant. Thismay be attributed to
antibacterial activity of proteoglycan [61, 62]. The
inhibition mechanism here is based on the binding of
proteoglycan resulting in proteins and essential nutrients
within theE. coli cells leaking, causing apoptosis [63].
The OD value for the treatment of PRII-PRO/CA-
STA (STA loaded in outer layer, PRO loaded in inner
layer) was a little higher than that of PRII-STA/CA-
PRO, indicating the inhibition effects of the former
was a little weaker than that of latter. This may be due
to the release rate of PRO loaded in outer layer was
quicker than that of in inner layer, just as the drug
release results showed.
The inhibition effects of printed membrane on
E. coli can be visualized in the results showed in
figure 9 and blank control group (Violet Red Bile agar
only) showed in figure S10b. Compared to the control
and negative group (figure 9(b)), a clear inhibition
zone is observed in each of the treatment groups. It
confirmed the printedmembranes possessed adequate
inhibition effects on E. coli. The inhibition effects of
drug-loading (PRII-STA/CA-PRO) semi-circle and
whole-circle membrane on E. coli was showed in
figures S9 and S10. The OD value (figure S9(b)) of
treatment of semi-circle and whole-circle membrane
with 0.1 g were 69.0±3.2% and 67.5±7.1%,
respectively, with respect to the control. The
Figure 9. (a)Effects ofmembrane ofODvalue of E. coli, plate Violet Red Bile agar treated by (b) unloaded and (c) drug-loaded
membrane onBBL agarmediumbase using plate coatingmethodwith cultured for 48 h.
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inhibition effects were visible from the less dense
E. coli colony counts (figure S10(e) and (f)).
4. Conclusions
In this study, a novel treatment system for improving
gastrointestinal tract microbial ecosystem in humans
was investigated.Core–shellCA-STA/PRII-PROmem-
braneswithhybrid patternswere successfully developed
using EHD printing. The speed order priority for drug
release rate of the printed membrane was whole-
circle>semi-circle>square, which confirmed the
modulation of drug release via the geometry of the
membranematrix.Theprinteddrug-loadedmembrane
possessed good biocompatibility on L929 cells and
excellent improvement effects on Bifidobacterium bifi-
dum, alongside adequate inhibition effects on E. coli.
Compared to the control, the proliferation ratio of
Bifidobacterium bifidum can be raised to 294.2% and
242.7%, respectively, at the treatment of 0.1 g PRII-
STA/CA-PROandPRII-PRO/CA-STA.The inhibition
effects on E. coliwas 37.0% and 27.5%, at the treatment
of 0.1 g PRII-STA/CA-PRO and PRII-PRO/CA-STA,
respectively. This result confirmed the feasibility of
improving proliferation of probiotics (Bifidobacterium
bifidum) combining with inhibiting growth of patho-
genic (E. coli) in a single dosage for using dual drug
loading. The core–shell structures developed here can
be extremely advantageous in efficient therapy for
gastrointestinal conditions.
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